Stocks Screener

Specify Company / Ticker to Get the Summary

Internet Computer ICP
Bitcoin Cash BCH
Litecoin LTC
Field stub for analysis

Dividend History RLMD

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021

Dividend Analytics RLMD

Max Ratio

5Y Dividend Growth

Consecutive Years

5Y Average Payout Ratio

Forward Annual Dividend Yield
Consecutive Years
Forward Annual Dividend – USD
Consistent Years
Dividend CAGR 3Y
Continuous Dividends
Dividend CAGR 5Y
Payout Ratio TTM
Dividend CAGR 10Y
Ex Dividend Date

Relmada Therapeutics Inc

RLMD
Current price
0.67 USD +0.07 USD (+11.68%)
Last closed 0.61 USD
ISIN US75955J4022
Sector Healthcare
Industry Biotechnology
Exchange NASDAQ
Capitalization 20 910 708 USD
Yield for 12 month -84.63 %
1Y
3Y
5Y
10Y
15Y
RLMD
21.11.2021 - 28.11.2021

Relmada Therapeutics, Inc. operates as a clinical-stage biotechnology company in the United States. The company focuses on the development of NDV-01, a controlled-release intravesical formulation of gemcitabine and docetaxel, which is in Phase 2 clinical trial for patients with aggressive forms of non-muscle invasive bladder cancer; and sepranolone, a neurosteroid epimer of allopregnanolone, which is Phase 2b-ready for the potential treatment of Prader-Willi Syndrome, Tourette Syndrome, excessive tremor, and other diseases related to excessive GABAergic activity. It also develops REL-P11, a modified-release formulation of psilocybin that has completed Phase 1 safety study for the treatment of metabolic disease. Relmada Therapeutics, Inc. was founded in 2004 and is headquartered in Coral Gables, Florida. Address: 2222 Ponce de Leon Blvd., Coral Gables, FL, United States, 33134

Check your investment idea

Find the best to beat the market
TSLA TSLA Tesla Motors
AAPL AAPL Apple
MSFT MSFT Microsoft

Analytics

WallStreet Target Price

1.00 USD

P/E Ratio

Dividend Yield

Financials RLMD

1 year
3 years
5 years
10 years
15 years
Results 2019 Dynamics
* The data for this period has not yet been published

Key Figures RLMD

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021

Current Year

Last Year

Current Quarter

Last Quarter

Current Year

Last Year

Current Quarter

Last Quarter

EBITDA -161 247 824 USD
Operating Margin TTM
Price to Earnings
Return On Assets TTM -88.24 %
PEG Ratio
Return On Equity TTM -160.26 %
Wall Street Target Price 1.00 USD
Revenue TTM
Book Value 0.68 USD
Revenue Per Share TTM
Dividend Share
Quarterly Revenue Growth YOY
Dividend Yield
Gross Profit TTM
Earnings per share -2.51 USD
Diluted Eps TTM -2.51 USD
Most Recent Quarter I 2025
Quarterly Earnings Growth YOY
Profit Margin

Stock Valuation RLMD

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Trailing PE
Forward PE
Enterprise Value Revenue
Price Sales TTM
Enterprise Value EBITDA 0.54
Price Book MRQ 0.93

Technical Indicators RLMD

For 52 Weeks

0.24 USD 4.47 USD
50 Day MA 0.59 USD
Shares Short Prior Month 1 127 001
200 Day MA 1.23 USD
Short Ratio 0.92
Shares Short 695 464
Short Percent 2.14 %